Clinical trials: Hodgkin Lymphoma
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Mantle Cell Lymphoma
A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients
This is an open label, multicenter, fixed dose and dose escalation, phase I/II study. The study will be conducted in 3 steps. The first one (step A) will be to ensure the safety of the combination of Obinutuzumab (GA101) and…
- Trial name
- OAsIs (NCT02558816)
- Testing
- Ibrutinib + GA101 +GDC-0199
- Where
- 9 sites in France, United Kingdom
- Volunteers
- 48 people
- Sponsor
- Nantes University Hospital
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
This randomized phase II trial includes a blood stem cell transplant from an unrelated donor to treat blood cancer. The treatment also includes chemotherapy drugs, but in lower doses than conventional (standard) stem cell…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT03246906
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Severe Adverse Event
Gender Bias in the Overuse Studies Conducting in Primary Care
The purpose of this study is to analyze whether the differences between men and women in the frequency of adverse events due to ignoring "Do not do" recommendations in primary care setting are due to biological causes or gender…
- Trial name
- OVERGEND (NCT05233852)
- Testing
- "Do not do" recommendation
- Where
- Spain
- Volunteers
- 1,538 people
- Sponsor
- Universidad Miguel Hernandez de Elche
Non-Hodgkin Lymphoma
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning for autologous stem cell transplantation in patients with non-Hodgkin lymphoma.
- Trial name
- NCT01178658
- Testing
- Busulfan, etoposide, cytarabine, and melphalan
- Where
- 5 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- Seoul National University Hospital
CLL, SLL
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
The primary objective of this study is to determine the recommended phase 2 dose (RP2D) and characterize the safety profile of TG-1801. As per protocol v3.0, ublituximab will be discontinued.
- Conditions
- CLL, SLL, Richter's Transformation, Indolent Lymphoma
- Trial name
- NCT04806035
- Testing
- TG-1801, Ublituximab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- TG Therapeutics, Inc.
Non-hodgkin Lymphoma
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
The safety and efficacy of the chimeric antigen receptor (CAR)-T, a CD19-targeting, TRAC and Power3 (SPPL3) double genes deleted allogeneic CAR-T cell product, are undergoing rigorous evaluation in non-Hodgkin's lymphoma (NHL)…
- Trial name
- NCT06323525
- Testing
- TCR reserved and Power3 (SPPL3) gene knock-out allogeneic CD19-targeting CAR-T cell (ATHENA-2 CAR-T), Fludarabine, Cyclophosphamide
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Non-Hodgkin's Lymphoma
Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy
This was a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-sensitive indolent B-cell non…
- Trial name
- HOMER (NCT01200589)
- Testing
- Ofatumumab, Rituximab
- Where
- 155 sites in United States, Belgium and 14 more
- Volunteers
- 438 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Lymphoma
A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
This is an open label, dose escalation, phase I study to determine the recommended Phase 2 dose (PR2D) by assessing the DLT, safety and efficacy of AC0010 in patients with B-cell lymphoma.
- Trial name
- NCT03060850
- Testing
- AC0010MA
- Where
- 2 sites in China
- Volunteers
- 184 people
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic
Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (PK) of brentuximab vedotin as a single agent in Chinese participants with relapsed/refractory CD30+ Hodgkin Lymphoma (HL) or Systemic Anaplastic…
- Trial name
- NCT02939014
- Testing
- Brentuximab Vedotin
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Takeda
Follicular Lymphoma
Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment…
- Trial name
- NCT05994235
- Testing
- Mosunetuzumab, Tazemetostat Pill
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma
131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of less than 5% of non-Hodgkin lymphoma in Korea.
- Trial name
- NCT01678417
- Testing
- 131I-rituximab
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Korea Cancer Center Hospital
Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT02851589
- Testing
- PCAR-019 (anti-CD19 CAR-T cells)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Lymphoma
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell transplant helps stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392691
- Testing
- ibritumomab tiuxetan, rituximab, melphalan
- Where
- 10 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Diffuse Large B-cell Lymphoma, HIV
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
The purpose of this study is to establish the safety of rituximab plus cyclophosphamide, doxorubicin, vincristine,prednisone (R-CHOP) in HIV-infected and HIV-uninfected diffuse large B-cell lymphoma (DLBCL) patients in Malawi.
- Trial name
- NCT02660710
- Testing
- R-CHOP
- Where
- Malawi
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
B-cell Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
This study is an open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic profile in the body after infusion of RS001 injection, and preliminary efficacy in…
- Trial name
- NCT06894693
- Testing
- RS001 injection
- Volunteers
- 13 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
This multi-center, open-label, randomized study will evaluate the participant preference with subcutaneous versus intravenous administration of MabThera/Rituxan (rituximab) in participants with CD20+ diffuse large B-cell lymphoma…
- Trial name
- NCT01724021
- Testing
- Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP), Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP), Bendamustine
- Where
- 246 sites in Argentina, Australia and 30 more
- Volunteers
- 743 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, B-Cell, Multiple Myeloma
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Chimeric Antigen Receptor T-Cell (CAR-T) therapy has transformed the management of large B-cell lymphoma, and multiple myeloma by achieving remarkable responses, yet inconsistent durability and severe toxicities remain major…
- Trial name
- (MICRO-CART) (NCT07871747)
- Testing
- Live Biotherapeutic Product (LBP)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Diffuse Large B-cell Lymphoma
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
This is a prospective, multicenter, single-arm clinical study on the treatment of newly diagnosed diffuse large B-cell lymphoma with high-risk of CNS relapse defined by CNS-IPI using Orelabrutinib in combination with R-CDOP…
- Trial name
- NCT06290817
- Testing
- Orelabrutinib combined with R-CDOP regimen
- Where
- 6 sites in China
- Volunteers
- 62 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Calcified Coronary Artery Disease (Grade 3)
A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions
The objective of this prospective, multicenter, randomized, open-label trial is to evaluate the completeness of stent expansion following a strategy of lesion preparation with either a Super High-Pressure NC PTCA Balloon (OPN NC)…
- Trial name
- ISAR-CALC (NCT03487432)
- Testing
- Super High-Pressure NC PTCA Balloon (OPN NC), Scoring PTCA Balloon (NSE Alpha)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 74 people
- Sponsor
- Deutsches Herzzentrum Muenchen
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.